According tomedia reports, there are some strict limitations in the vaccine development process, which means that for at least a year to 18 months, we will not see any preventive immunotherapy against the new coronavirus. However, The vaccine provided by Moderna has become the first new coronary pneumonia vaccine in the United States to be clinically tested in the first stage of human scant. The company provided new information on Monday that it would seek to provide vaccines to a limited population as soon as possible, possibly including the possibility of providing an experimental COVID-19 vaccine to health care providers by the fall.
The company will consider doing so under the U.S. Food and Drug Administration’s (FDA) emergency use authorization, similar to the way some test procedures are approved for immediate use, bypassing the typical process of approving such diagnostic tools. Moderna Solutions, developed in collaboration with the U.S. National Institute of Allergy and Infectious Diseases, is already the fastest potential vaccine to enter human clinical trials.
They proposed a vaccine that uses messenger RNA, rather than relying on small or inactive samples of the COVID-19 virus itself, the source of most of the existing effective vaccines. The mRNA approach means that no real virus is introduced into subjects receiving the vaccine, which means they do not actually get the virus from the vaccine itself, which is a problem at any traditional stage of testing and development.
On Monday, Moderna began providing vaccines to volunteers in Washington state who are participating in the first phase of human clinical trials. Despite the speed of human testing and the unconventional detours during the animal testing phase, it will take at least a year to commercialize. However, if health care providers choose to use them only on a limited schedule, it may help provide additional protection for front-line personnel at greater risk of exposure, provided that Moderna’s vaccine is effective and proven safe in current human tests.
Moderna’s solution is to produce virus-like but harmless proteins and to fire antibodies that are resistant to both proteins and the actual virus itself. Other RNA-based vaccines and other types of immunotherapy are currently being developed by other research institutions, but so far only the Moderna vaccine has been in clinical trials. The Boston-based company has been working on mRNA-based cancer cell treatments and will be available in December 2018.